Loss of a Subunit of Vacuolar Atpase Identifies Unexpected Biological Signatures of Reduced Organelle Acidification in Vivo
Total Page:16
File Type:pdf, Size:1020Kb
bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.397463; this version posted November 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Loss of a subunit of vacuolar ATPase identifies unexpected biological signatures of reduced organelle acidification in vivo Short title: Loss of vacuolar ATPase function and reduced acidification in vivo Pottie Lore1,2, Van Gool Wouter1,2, Vanhooydonck Michiel1,2, Hanisch Franz-Georg3, Goeminne Geert4,5, Rajkovic Andreja 6, Coucke Paul1,2, Sips Patrick1,2* and Callewaert Bert1,2*. 1. Center for Medical Genetics Ghent, Ghent University Hospital, 9000 Ghent, Belgium 2. Department of Biomolecular Medicine, Ghent University, 9000 Ghent 3. Institute of Biochemistry II, Medical Faculty, University of Cologne, 50931 Köln, Germany. 4. VIB Metabolomics Core Ghent, 9052 Ghent, Belgium. 5. Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Ghent, Belgium. 6. Department of Food technology, Safety and Health, Faculty of Bioscience Engineering, University of Ghent, 9000 Ghent, Belgium * Sips P and Callewaert B contributed equally to this work. Corresponding author Callewaert Bert Center for Medical Genetics Ghent University Hospital Corneel Heymanslaan 10 9000 Gent, Belgium [email protected] Keywords ATP6V1E1, danio rerio, acidification, transcriptome, metabolome, sphingolipids, endo(lyso)somes Funding B.C. is a senior clinical investigator of the Research Foundation Flanders. This work was supported by a starting grant of the Special Research Fund, Flanders of Ghent University (grant 01N04516C to B.C.), by a Methusalem Grant (BOFMET2015000401) from Ghent University, by a junior fundamental research project grant of the Fund for Scientific Research (G035620N) and by the European Union’s Horizon 2020 research and innovation program, under the Marie Skłodowska-Curie grant agreement No. 794365 to P.S. Conflicts of Interest: The authors declare no conflict of interest bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.397463; this version posted November 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The inability to maintain a strictly regulated endo(lyso)somal acidic pH through the proton-pumping action of the vacuolar-ATPases has been associated with various human diseases including heritable connective tissue disorders, neurodegenerative diseases and cancer. Multiple studies have investigated the pleiotropic effects of reduced acidification in vitro, but the mechanisms elicited by impaired endo(lyso)somal acidification in vivo remain poorly understood. Here, we show that loss of atp6v1e1b in zebrafish leads to early mortality, associated with craniofacial dysmorphisms, vascular anomalies, cardiac dysfunction, hypotonia and epidermal structural defects, reminiscent of the phenotypic manifestations in cutis laxa patients carrying a defect in the ATP6V1E1 gene. Mechanistically, we found that in vivo genetic depletion of atp6v1e1b leads to N-glycosylation defects and reduced maturation of endosomal and lysosomal vesicles, but retains the hypoxia-mediated response. In order to gain further insights into the processes affected by aberrant organelle acidification, we performed an untargeted analysis of the transcriptome and metabolome in early atp6v1e1b-deficient larvae. We report multiple affected pathways including but not limited to oxidative phosphorylation, sphingolipid and fatty acid metabolism with profound defects in mitochondrial respiration. Taken together, our results identify new complex biological effects of reduced organelle acidification in vivo, which likely contribute to the multisystemic manifestations observed in disorders caused by v-ATPase deficiency. Introduction The intracellular pH of specific subcellular compartments is maintained by the proton-pumping action of the vacuolar-ATPases (v-ATPase), thereby regulating a range of molecular processes including activation of enzyme activity, protein folding, vesicle trafficking, and support of organelle function and integrity. V-ATPases consist of ubiquitously expressed multisubunit complexes, composed of a membrane-associated V0 domain and a cytosolic (catalytic) V1 domain. Hydrolysis of ATP by the complex generates proton pumping activity against a concentration gradient in the lumen of endo(lyso)somes, secretory vesicles, Golgi apparatus and across the plasma membrane of specialized cells including osteoclasts, epididymal clear cells and renal epithelial intercalating cells [1]. Various human diseases are linked to defects in genes encoding subunits of the v-ATPase, including neurological disorders (e.g. encephalopathy with epilepsy (ATP6V1A [MIM: 618012]), X-linked mental retardation Hedera type (ATP6AP2 [MIM: 300423]), and X-linked Parkinson Disease with spasticity (ATP6AP2 [MIM: 300911])), congenital disorders of glycosylation (ATP6AP1 [MIM: 300972] and ATP6AP2 [MIM: 301045]), disorders in which the secretion of protons in the extracellular environment is disrupted (e.g. distal renal tubular acidosis and hearing loss (ATP6V1B1 [MIM: 192132] and ATP6V0A4 [MIM: 605239]), syndromic osteopetrosis (ATP6V0A3 [MIM:259700]), Zimmermann- Laband syndrome (ATP6V1B2 [MIM: 616455]), dominant deafness-onychodystrophy syndrome (ATP6V1B2 [MIM: 124480])) and connective tissue disorders (e.g. autosomal recessive (AR) cutis laxa (CL) syndrome type 2A (ATP6V0A2 [MIM: 219200]), ARCL type 2C (ATP6V1E1 [MIM: 617402]), and ARCL type 2D (ATP6V1A [MIM: 617403])) [2-12]. ARCL type 2 shows variable glycosylation bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.397463; this version posted November 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. abnormalities [10, 13, 14], and is characterized by skin wrinkles or loose redundant skin folds, variable level of mental impairment, delayed neuromotor development, sensorineural hearing loss, skeletal abnormalities, facial dysmorphology, hypotonia, and cardiopulmonary involvement including pneumothorax, hypertrophic cardiomyopathy, and aortic root dilation [10, 11, 15, 16]. Finally, v- ATPases have been implicated in cancer growth and metastasis in a variety of contexts [17]. Higher v- ATPase expression and relocation to the plasma membrane is observed in proliferating cancer cells including breast, prostate, liver, pancreatic, melanoma, and esophageal cancers [18]. V-ATPase activity in the plasma membrane promotes cell survival since the resulting alkalization of the intracellular environment supports the Warburg effect by reducing the excess acid load caused by glycolytic lactic acid production [19]. Intracellular v-ATPases further regulate key physiological cell signaling pathways. V-ATPase are involved in downstream Notch signaling [20-23], Wnt signaling [18, 24-29], activation of mechanistic target of rapamycin complex 1 (mTORC1), and AMP-activated protein kinase (AMPK) signaling [17]. Recent studies have highlighted a novel mechanism linking v-ATPase inhibition, hypoxia-inducible factor (HIF) signaling and iron deficiency. Using in vitro experiments, it was shown that genetic and pharmacological inhibition of v-ATPases impairs endo(lyso)somal acidification which leads to defective cellular iron uptake via the transferrin system. Iron depletion results in reduced prolyl hydroxylase activity, leading to stabilization of HIF and activation of HIF-dependent signaling mechanisms [30-32]. This raises the question whether in vivo v-ATPase deficiency impairs iron homeostasis and perturbates HIF-mediated response, and if this represents the major mode of action in genetic disorders related to defects in v-ATPase subunits. Complete loss of the murine proteolipid 16 kDa subunit of the v-ATPase V0 complex is embryonically lethal [33]. Since external fertilization and transparent development allow us to study embryonic development in zebrafish, we modelled genetically depleted atp6v1e1b zebrafish. Despite early mortality, this model mimics ARCL type 2C with hypotonia, craniofacial abnormalities, vascular anomalies, and an altered dermal connective tissue structure. Untargeted analysis of the transcriptome, metabolome, and lipidome furthermore indicates alterations in oxidative phosphorylation, fatty acid metabolism, and sphingolipid metabolism in this in vivo model of v-ATPase deficiency. Results Genetic loss of atp6v1e1b in zebrafish leads to early mortality and mimics the human phenotype of ATP6V1E1-related cutis laxa syndrome. We genetically depleted atp6v1e1b, a subunit of the v-ATPase that connects the transmembrane domain with the cytosolic domain, in zebrafish to identify pleiotropic manifestations of reduced organelle acidification in vivo. We generated a zebrafish line harboring a two base-pair insertion followed by a three base-pair deletion in exon 5 of atp6v1e1b (atp6v1e1bcmg78/+), c.334insGG; c.337-340delCGG, which led to nonsense-mediated decay (NMD) due to a premature stop codon (Supplemental Figure 1A-B). We further obtained a zebrafish line with viral insertion in the 5’UTR of atp6v1e1b bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.397463; this version posted November 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.